Abstract: In order to reduce the dependence of the sol-gel transition temperature of the poloxamer hydrogel on the concentration, the poloxamer (P₄₀₇) was used as the substrate, and hexanoyl ethylene glycol chitosan (HGC) was compounded with poloxamer to prepare HGC/P₄₀₇ composite hydrogel. FTIR, SEM and tube inversion method were used to investigate the properties of HGC/P₄₀₇ composite hydrogel in different mass ratios, and the in vitro drug release performance of HGC/P₄₀₇ composite hydrogel was characterized by UV-vis spectroscopy. The results show that sol-gel transformation can occur in HGC/P₄₀₇ hydrogel based on 3% poloxam by controlling the addition of HGC, and the sol-gel transition temperature of HGC/P₄₀₇ hydrogel is between 32℃ and 37℃. HGC/P₄₀₇ composite hydrogel has high porosity with interconnected pores which size ranging from 10 to 90 µm. The release amount of the anticancer drug gemcitabine of HGC/P₄₀₇ composite hydrogel is 82%~90.6%, and the sustained release time can reach about 80 h. HGC/P₄₀₇ composite hydrogel has important application prospects in the field of injectable drug carriers.